NNC0581-0001(NNC0581-0001) - 药物靶点：MTARC1_在研适应症：非酒精性脂肪性肝炎_专利_临床

概要

基本信息

药物类型

siRNA

别名

NN-6581、NN6581、NNC0581 0001

+ [1]

靶点

MTARC1

作用方式

抑制剂

作用机制

MTARC1 inhibitors(mitochondrial amidoxime reducing component 1 inhibitors)

治疗领域

消化系统疾病

在研适应症

非酒精性脂肪性肝炎

非在研适应症-

原研机构

Novo Nordisk A/S

在研机构

Novo Nordisk A/S

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

使用我们的RNA技术数据为新药研发加速。

登录

或

查看完整样例数据

关联

2

项与 NNC0581-0001 相关的临床试验

NCT06891365

/ Recruiting临床1期

Investigation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of NNC0581-0001 in Participants With Hepatic Steatosis and Suspected Steatohepatitis

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of NNC0581-0001 in participants with hepatic steatosis and suspected steatohepatitis (increased liver fat and suspected inflammation). NNC0581-0001 will be given in 2 different dose levels as injection under the skin (once per month for 3 months). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance. NNC0581-0001 is a new medicine which cannot be prescribed by doctors. The study will last about 58 weeks.

开始日期2025-03-12

申办/合作机构

Novo Nordisk A/S

NCT05599945

/ Active, not recruiting临床1期

A First Human Dose Study Investigating Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous Injections of NNC0581-0001 in Healthy Adults and in Participants With Hepatic Steatosis

This study will assess the safety, tolerability, the pharmacokinetics from single injection (under the skin) of NNC0581-0001 and explores the pharmacodynamics in healthy participants and participants with hepatic steatosis (increased liver fat). Participants will either get NNC0581-001 or Placebo (dummy treatment). Which treatment participants get is decided by chance.NNC0581-0001 is a new medicine which cannot be prescribed by doctors. The study will last about 58 weeks.

开始日期2022-11-23

申办/合作机构

Novo Nordisk A/S

100 项与 NNC0581-0001 相关的临床结果

登录后查看更多信息

100 项与 NNC0581-0001 相关的转化医学

登录后查看更多信息

100 项与 NNC0581-0001 相关的专利（医药）

登录后查看更多信息

100 项与 NNC0581-0001 相关的药物交易

登录后查看更多信息